Percutaneous Coronary Intervention of Chronic Total Occlusions: When and How to Treat.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
06 2019
Historique:
received: 22 04 2018
revised: 24 07 2018
accepted: 24 07 2018
pubmed: 11 8 2018
medline: 9 6 2020
entrez: 11 8 2018
Statut: ppublish

Résumé

Chronic coronary total occlusions (CTO) are diagnosed in up to 20% of patients with coronary artery disease and have a detrimental effect on patients' quality of life and long-term prognosis. The exponential developments in CTO percutaneous coronary intervention (PCI) equipment, recanalization techniques, and operator expertise have been merged into the hybrid approach that represents a percutaneous revascularization algorithm for treating CTOs and has led to technical success over 90% at experienced centers. Therefore, patient selection for CTO PCI should be focused on anticipated patient benefit in terms of health status and long-term prognosis rather than coronary anatomic complexity. TABLE OF CONTENTS: This review will provide an overview of the clinical presentation and characteristics of patients with a CTO and will discuss the essential needs toward judicious patient selection for percutaneous CTO revascularization according to contemporary knowledge. Furthermore, the current high standard revascularization techniques in dedicated CTO PCI will be discussed.

Identifiants

pubmed: 30093292
pii: S1553-8389(18)30324-5
doi: 10.1016/j.carrev.2018.07.025
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

513-522

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Stefan P Schumacher (SP)

Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.

Wijnand J Stuijfzand (WJ)

Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.

Maksymilian P Opolski (MP)

Department of Interventional Cardiology and Angiology, Institute of Cardiology, Alpejska 42, 04-628 Warsaw, Poland.

Albert C van Rossum (AC)

Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.

Alexander Nap (A)

Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.

Paul Knaapen (P)

Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. Electronic address: p.knaapen@vumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH